Verve Therapeutics에 대한 매도 수량은 투자자에게 Verve Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Verve Therapeutics (NASDAQ:VERV) 주식, 공매도 수량 보고

Verve Therapeutics

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Equities

News

Markets

ETFs

ACHR

ARKK

AVAV

BLDE

NTLA

TDOC

TSLA

VERV

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:TSLA)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.

아크 인베스트가 예상을 넘는 2분기 배송 실적에도 $3.25백만 규모 테슬라 주식 매도 추가

$BTC

ABSI

ARKW

COIN

ROKU

월요일에는 캐시 우드가 주도하는 아크 인베스트(Ark Invest)가 몇 가지 중요한 거래를 했으며, 그 가운데 코인베이스 글로벌(NASDAQ:COIN)의 거래가 주목을 받았다. 이는 특히 암호화폐의 경우 격동적인 시장 시나리오 속에서 발생했다.
코인 거래

아크 인베스트는 비트코인이 $62,000 아래로 하락하면서 코인베이스 주식을 매도

$ETH

ARCT

ARKF

ARKG

ARKQ

ARKX

HOOD

MKFG

캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 수요일에 로빈후드 마켓(NASDAQ:HOOD) 및 줌 비디오 커뮤니케이션(NASDAQ:ZM)괴 관련하여 상당한 거래를 했다.
로빈후드 주식의 거래

아크 인베스트는 로빈후드 주식 150만 달러를 매도하며, 줌 주식 330만 달러 상당도 처분

Verve Therapeutics Inc

MGI MEDIA & GAMES INVEST by MGI MEDIA & GAMES INVEST SE

Verve Group SE

A new study <a href="https://tandfonline.com/doi/full/10.1080/21507740.2024.2303154">published</a> in AJOB Neuroscience reveals that most Americans are supportive of <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> use, a psychedelic compound derived from "magic mushrooms," in supervised, licensed settings. As PsyPost <a href="https://www.psypost.org/majority-of-americans-support-supervised-use-of-psilocybin-for-mental-health-and-well-being/">reported</a>, this approval, spanning across political lines, underscores public openness to the controlled use of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psilocybin for mental health treatment</a> and general well-being, despite remaining concerns for policy caution.
Psilocybin, a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule 1</a> drug in the U.S., has long been classified as having a high potential for abuse with no accepted medical use. However, <a href="https://www.benzinga.com/markets/cannabis/24/10/41216395/could-psilocybin-be-a-game-changer-for-millions-battling-depression-new-study-says-yes">recent clinical studies</a> suggest it may help alleviate symptoms of conditions such as treatment-resistant depression when administered under professional supervision. Unlike many medications, psilocybin is considered non-addictive, and studies have found it may also <a href="https://www.benzinga.com/markets/cannabis/24/09/41004196/psilocybin-found-to-be-as-effective-as-lexapro-in-treating-depression-researchers-say">enhance overall well-being</a> in healthy individuals.
This research aimed to explore public perceptions of psilocybin amid <a href="https://www.benzinga.com/markets/cannabis/24/08/40447902/psychedelics-and-mental-health-fda-stalls-but-states-forge-ahead">recent legislative progress</a>, such as Oregon&#8217;s law <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">allowing its therapeutic use</a>. Researchers surveyed 805 Americans, aged 18 to 92, providing background on psilocybin's effects, origin and legal status before asking about support for nationwide legalization.
<h3 class="wp-block-heading">Mental Health Treatment Vs. Well-Being Enhancement</h3>
Participants were presented with two scenarios involving supervised psilocybin use: one for mental health treatment and the other for personal well-being. A strong 89% of participants supported psilocybin use for mental health treatment, while 85% approved its use for well-being enhancement. Though medical use garnered slightly more support, both scenarios saw broad endorsement.
The results show bipartisan support for supervised psychedelic therapy, with younger and more liberal adults showing stronger approval. Older adults and conservatives were more cautious, while those valuing empathy and care were more supportive of psilocybin use in therapy
<h3 class="wp-block-heading">Navigating Caution Amid The Psychedelic Renaissance</h3>
The study also sheds light on the importance of tempering enthusiasm with scientific rigor. According to the researchers, the growing interest in psychedelics comes with the risk of overhyping benefits. Given the early stage of the field, both over- and understatements of trial results are not uncommon. As they noted, while psilocybin shows significant medical potential and a strong safety profile, current evidence doesn&#8217;t support rash conclusions beyond its use in the right context.
While the findings suggest broad public support for supervised psychedelic use, the study focused only on licensed environments, excluding unsupervised or recreational use. Future research could explore attitudes toward these higher-risk aspects.
<h3 class="wp-block-heading">Building Trust And Policy For The Future</h3>
The study authors stressed the need for trust-building and caution in shaping future policies. "If the field can overcome scientific inaccuracies, pursue rigorous research, and build trust—then psychedelics such as psilocybin may one day be seen as a mainstream means to treat mental illness and possibly also to promote overall well-being," they concluded.
With public support reaching bipartisan levels, the potential for psilocybin to become part of standard mental health care is closer to reality than ever, signaling a transformative shift in mental health treatment in the U.S.
Cover image made with AI

Cannabis

Psychedelics

Americans Favor Psilocybin For Mental Health Treatment, Study Finds

DA Davidson analyst Brian Holland maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Buy and raises the price target from $183 to $189.

Price Target

Analyst Ratings

FRPT

DA Davidson Maintains Buy on Freshpet, Raises Price Target to $189

Hut 8 Says Its Self-Mining Produced 100 BTC In October, Up From 85 BTC In September; Vega Site Buildout Advancing On Track For Q2 2025 Energization

DA Davidson analyst Michael Shlisky maintains Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Neutral and lowers the price target from $94 to $90.

DA Davidson Maintains Neutral on Federal Signal, Lowers Price Target to $90

DA Davidson maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $55 to $48.

NSSC

DA Davidson Maintains Buy on NAPCO Security Techs, Lowers Price Target to $48

Emerson and its affiliates currently own 57.4% of the Company's outstanding common shares, based on their most recent Schedule 13D filing dated November 5, 2024.
The Board of Directors of AspenTech will follow an appropriate governance process and carefully review the proposal. No action is required by AspenTech shareholders at this time. &nbsp;

AZPN

Aspen Technology Confirms Receipt Of $240/Share Unsolicited Acquisition Proposal From Emerson; Asks Shareholders Not To Take Any Action Pending Review

DA Davidson analyst Brent Thielman maintains Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) with a Neutral and raises the price target from $41 to $47.

DA Davidson Maintains Neutral on Summit Materials, Raises Price Target to $47

Guidance

PAAS

Pan American Silver Reaffirms Its 2024 Operating Outlook For Annual Production, Cash Costs And AISC, And Capital Expenditures

Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 3100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $716.10 million which beat the analyst consensus estimate of $699.01 million by 2.44 percent. This is a 16.19 percent increase over sales of $616.30 million the same period last year.

Earnings

Earnings Beats

Pan American Silver Q3 2024 Adj EPS $0.32 Beats $0.21 Estimate, Sales $716.10M Beat $699.01M Estimate

DA Davidson analyst Kevin Fitzsimmons maintains Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) with a Buy and lowers the price target from $41 to $38.

DA Davidson Maintains Buy on Origin Bancorp, Lowers Price Target to $38

DA Davidson analyst Gil Luria maintains Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) with a Neutral and raises the price target from $28 to $47.

PLTR

DA Davidson Maintains Neutral on Palantir Technologies, Raises Price Target to $47

The 2024 U.S. presidential election between Vice President Kamala Harris and former President Donald Trump remains one of the closest in history, raising concerns over whether the U.S. Supreme Court may play a decisive role in <a href="https://www.benzinga.com/topic/2024-election">determining the outcome. </a>
As voters head to the polls, election-related legal battles already hint at the possibility of judicial involvement, The New York Times <a href="https://www.nytimes.com/2024/11/05/us/politics/election-supreme-court.html">reports</a>.
What Happened: Several election cases have reached the Supreme Court in recent weeks, including a decision to allow Virginia's removal of over 1,600 voters from its rolls and rulings affecting candidates and voters in battleground states. 
The court decided against removing Robert F. Kennedy Jr. from ballots in key states and authorized provisional ballots in Pennsylvania, after some mail-in ballots were deemed invalid. These cases showcase the judiciary's cautious approach to electoral involvement, although the court's conservative majority could still play a critical role if a close race sparks significant litigation, according to The New York Times.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41759661/us-election-jitters-meet-interest-rate-cut-assurance-why-feds-powell-may-offer-tr">US Election Jitters Meet Interest-Rate Cut Assurance: Why Fed&#8217;s Powell May Offer Traders A Safe Harbor This Week</a>
The Supreme Court's involvement would hinge on an exceptionally narrow vote margin in a critical state, experts say. Prof. Richard Pildes of New York University told The New York Times that a paper-thin margin in a state like Pennsylvania, with its 19 electoral votes, could increase the likelihood of a court ruling influencing the presidential outcome.
Still, experts are cautious, noting that the Supreme Court generally aims to avoid direct involvement in elections.
Beyond the presidential race, the stakes extend to congressional control. Democrats seek to retain the Senate and flip the House, while Republicans push for gains in both chambers. The outcomes in Senate races, including those in Montana and Ohio, could shift control, particularly if Democratic seats in battleground states like Michigan and <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">Pennsylvania face Republican challenges.</a> 
Why It Matters: A Supreme Court decision might not only impact the presidency but also influence control over Congress, setting a precedent for election litigation. In a scenario reminiscent of the Bush v. Gore case in 2000, if margins are close enough, legal challenges could escalate to the highest court. 
The potential for either party to control both chambers or split Congress suggests significant implications for the future of U.S. legislation and governance, The New York Times notes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41756372/robinhoods-election-contracts-hit-200-million-trades-on-election-day">Robinhood&#8217;s Election Contracts Hit 200 Million Trades On Election Day</a></li>
</ul>
This article was generated using artificial intelligence and was reviewed by Benzinga editors.
Photo: Shutterstock

Government

Politics

Legal

Supreme Court Could Step In If 2024 Election Remains Deadlocked

SMCI

Super Micro Computer CEO Says Don't Expect Negative Allocation From NVIDIA

Super Micro Computer CEO Says He Has An 'Open Mind' About Separating CEO And Chairman Roles

Gerdau Reports Q3 Adjusted EBITDA Of R$3.0B, Up 14.9% Q/Q

Murchinson Ltd. holds approximately 7.1% of the outstanding shares of Nano Dimension.

NNDM

Murchinson Urges Nano Dimension Shareholders To Vote For Its Independent Nominees; Sends Letter Highlighting Company's Questionable Acquisitions

TD Bank Expects Catastrophe Claims Of $388M After Reinsurance And Before Tax To Be Reflected In Wealth Management & Insurance Segment's Q4 Results

Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) reported third-quarter financial results after the market close Tuesday, the same day Donald Trump is facing off against Kamala Harris in the <a href="https://www.benzinga.com/news/24/11/41758791/whats-going-on-with-trump-media-technology-group-stock-tuesday">2024 presidential election.</a>
What Happened: Trump Media &amp; Technology Group announced third-quarter net sales of $1.01 million, down 6% year-over-year, according to data<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company <a href="https://s3.amazonaws.com/sec.irpass.cc/2660/0001140361-24-045260.pdf">said </a>all of its revenue came from advertising on the Truth Social platform in the quarter.
The company reported a loss of 10 cents per share compared to a loss of 30 cents per share in last year's third quarter.
Trump Media &amp; Technology Group, which was co-founded by the former president, highlighted the importance of Trump for the company's success.
"TMTG's success depends in part on the popularity of our brand and the reputation and popularity of President Donald J. Trump. The value of TMTG's brand may diminish if the popularity of President Donald J. Trump were to suffer," the company said.
Trump is able to post politically related posts on any social media site at any time, including outside of Truth Social, the filing said. 
The filing lists a date of Feb. 2, 2025 for when Trump may "terminate the Exclusivity Obligation" with 30 days prior written notice for his non-political posts to appear first on Truth Social.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: The quarterly filing said the company plans to roll out its streaming content in three phases.
<ul>
<li>Phase 1: Introduce Truth Social for streaming live TV to the Truth Social app for Android, iOS and Web</li>
<li>Phase 2: Release standalone Truth Social over-the-top streaming apps for phones, tablets and other devices</li>
<li>Phase 3: Release Truth Social streaming apps for home TV</li>
</ul>
The company said it completed phase 1 in August, phase 2 in October and as of Oct. 23, phase 3 has seen the Truth+ streaming platform released on Apple TV, Android TV and Amazon Fire TV.
Future growth initiatives from the company include growing the initial Truth Social platform, increasing product offerings and pursuing strategic acquisitions and/or partnerships.
The company said it plans to expand the business operations globally.
Trump Media &amp; Technology Group ended the third quarter with $672 million in cash, cash equivalents and short-term investments.
DJT Price Action: Shares of Trump Media &amp; Technology Group saw increased volatility Tuesday ahead of the 2024 election with shares halted twice Tuesday.
Shares traded between $31.45 and $40.74 on Tuesday before closing down 1% to $33.94.
The stock is trading 2,.2% higher after hours at $4.69. 
Trump Media &amp; Technology Group stock is likely to experience increased volatility during the week as investors await the results of the 2024 election, with a potential Trump win viewed as a positive for the stock and a Trump loss viewed as a negative for the stock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41732623/bakery-that-often-predicts-election-outcomes-has-this-candidate-winning-in-trump-harris-battle-d" target="_blank" rel="noreferrer noopener">Bakery That Often Predicts Election Outcomes Has This Candidate Winning In Trump, Harris Battle: ‘Doughmacracy For All!'</a></li>
</ul>

Social Media

Movers

Trading Ideas

DJT Stock Volatile On Election Day: Donald Trump's Media Company Reports Q3 Earnings, Growth Initiatives

Jones Trading analyst Jason Weaver maintains Franklin BSP Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBRT#NYSE">FBRT</a>) with a Buy and maintains $15 price target.

FBRT

Jones Trading Maintains Buy on Franklin BSP Realty Trust, Maintains $15 Price Target

Super Micro Computer CEO Says Its Servers Are Ready For Production When NVIDIA Chips Arrive

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Verve Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/verv-stock-quote/">VERV</a>) just reported results for the second quarter of 2024.<ul><li>Verve Therapeutics reported earnings per share of -59 cents. This was above the analyst estimate for EPS of -68 cents.</li><li>The company reported revenue of $6.69 million.</li><li>This was 178.83% better than the analyst estimate for revenue of $2.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/verv-stock-earnings-verve-therapeutics-for-q2-of-2024/">VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Verve Therapeutics (VERV – Research Report), 4D Mole...

Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)

In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Verve Therapeutics (VERV – Research Report), with a price tar...

RBC Capital Remains a Buy on Verve Therapeutics (VERV)

LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Verve Therapeutics (VERV – Research Report) today and set a price target of...

Buy Rating Affirmed for Verve Therapeutics Amidst Clinical Progress and Strong Financials

THE LAWSUIT: A class action securities lawsuit was filed against Verve Therapeutics, Inc. (VERV) that seeks to recover losses of Verve Therapeutics...

Levi & Korsinsky LLP Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming Deadline

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio

Verve Therapeutics ($VERV) is revolutionizing the approach to cardiovascular disease treatment through pioneering gene-editing therapies that provi...

Verve Therapeutics' (VERV) Gene-Editing Therapies Could Be a Game Changer

Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers

Wall Street Breakfast: The Week Ahead

Verve Therapeutics beats Q3 estimates

AERG

ALXO

AZUL

BIRK

BMRN

BRZE

CARM

COST

ETON

FDMT

GRDN

HUBS

IART

IMRX

INTU

LGCY

LUNR

MPAA

NBIX

NXST

PGHL

SFIX

TURB

VSTO

ZETA

Press Releases

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV

VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV

Verve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERV

Small Cap

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

Comments

Verve Therapeutics

매도 수량

Verve Therapeutics (NASDAQ:VERV) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌